Evidence map›Paper›PMID 34249004›Full record

ArticleFrontiers in immunology2021

Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based

Shakyra Richardson, Fnu Medhavi, Tayhlor Tanner, Stephanie Lundy, Yusuf Omosun, Joseph U Igietseme, Darin Carroll, Francis O Eko

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shakyra RichardsonDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Fnu MedhaviDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Tayhlor TannerDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Stephanie LundyDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Yusuf OmosunDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Joseph U IgietsemeNational Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States.
Darin CarrollNational Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States.
Francis O EkoDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States.
Morehouse School of Medicine · USCenters for Disease Control and Prevention · US

Funding

IMMUNITY TO CHLAMYDIA ABORTUSR01AI126897 · NIAID · MOREHOUSE SCHOOL OF MEDICINE · PI EKO, FRANCIS O. · 2016 to 2019
$1.7M
NIAID NIH HHS R01 AI126897
6 · The paper itself

Abstract

Efficacious vaccines are needed to control genital chlamydial diseases in humans and the veterinary industry. We previously reported a

Indexed as

Chlamydia InfectionsAdjuvants, VaccineAnimalsBacterial VaccinesChlamydiaFemaleMembrane ProteinsMiceMice, Inbred C57BLVibrio choleraeAdjuvants, VaccineBacterial Vaccinesflt3 ligand proteinMembrane ProteinsadjuvantChlamydia abortusFlt3LPmp18Dvaccine delivery

Identifiers

PMID34249004
PMCPMC8264281
OpenAlexW3173372814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.